QuanterixQTRX
About: Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory, Homebrew - Custom Assay Development, and Uman NF-Light.
Employees: 141
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 4 (+2) [Q3]
55% more call options, than puts
Call options by funds: $521K | Put options by funds: $337K
1.42% more ownership
Funds ownership: 85.15% [Q2] → 86.57% (+1.42%) [Q3]
0% more capital invested
Capital invested by funds: $430M [Q2] → $431M (+$106K) [Q3]
5% less funds holding
Funds holding: 154 [Q2] → 146 (-8) [Q3]
21% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 53
26% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 31
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
TD Cowen Daniel Brennan 50% 1-year accuracy 3 / 6 met price target | 43%upside $16 | Hold Maintained | 13 Nov 2024 |
Financial journalist opinion
Based on 28 articles about QTRX published over the past 30 days
